S-1: Dar Bioscience Files for Resale of 2.75 Million Shares of Common Stock

Dar Bioscience has filed a registration statement for the resale of up to 2.75 million shares of its common stock by Lincoln Park Capital Fund, LLC.

Summary

• Dar Bioscience has filed a registration statement for the resale of up to 2,750,000 shares of its common stock.
• These shares are being offered by Lincoln Park Capital Fund, LLC, the selling stockholder.
• The shares include 137,614 commitment shares already issued to Lincoln Park and up to 2,612,386 shares that may be issued in the future under a purchase agreement.
• Dar Bioscience will not receive any proceeds from the sale of these shares by Lincoln Park.
• The company may receive up to $15 million in gross proceeds from future sales of shares to Lincoln Park under the purchase agreement.
• The company intends to use any proceeds for working capital and general corporate purposes.
• The purchase agreement allows Dar Bioscience to sell shares to Lincoln Park at its discretion, subject to certain limitations and market conditions.
• The price per share for these sales will be determined by the market price of Dar Bioscience's common stock at the time of sale.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol DARE.
• As of November 14, 2024, the last reported sale price of the common stock was $3.57 per share.

Sentiment

Score: 4

Explanation: The document outlines a necessary but potentially dilutive financing arrangement. While the company gains access to capital, the risk of share price decline and dilution lowers the sentiment.

Positives

• The purchase agreement with Lincoln Park provides a potential source of funding for Dar Bioscience, up to $15 million.
• The company has the flexibility to control the timing and amount of share sales to Lincoln Park.
• The company can terminate the purchase agreement at any time after commencement without penalty.
• The company has a diverse portfolio of product candidates in women's health.
• The company has a product, XACIATO, that has been approved by the FDA and is being commercialized by Organon.

Negatives

• The resale of shares by Lincoln Park could cause dilution to existing stockholders.
• The sale of shares by Lincoln Park could cause the price of Dar Bioscience's common stock to fall.
• The company will not receive any proceeds from the resale of shares by Lincoln Park.
• The company is dependent on raising additional capital to fund its operations.
• The company is subject to a number of risks common to biopharmaceutical companies.
• The company may not have access to the full $15 million available under the purchase agreement.
• The company may need to seek stockholder approval before issuing more than 1,711,172 shares of common stock under the purchase agreement.

Risks

• The sale of common stock to Lincoln Park may cause dilution and the subsequent sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.
• It is not possible to predict the actual number of shares of common stock we may sell to Lincoln Park under the Purchase Agreement, or the actual gross proceeds resulting from those sales.
• We may not have access to the full amount available under the Purchase Agreement with Lincoln Park.
• We may require additional financing to sustain our operations, without which we may not be able to continue operations, and the terms of subsequent financings may adversely impact our stockholders.
• If we fail to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market, our common stock could be suspended and delisted.
• The sale of our common stock in ATM offerings may cause substantial dilution to our existing stockholders, and such sales, or the anticipation of such sales, may cause the price of our common stock to decline.
• Our management will have broad discretion over the use of the net proceeds, if any, from sales of shares of our common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be used effectively.

Future Outlook

The company expects to use any proceeds from the sale of shares to Lincoln Park for working capital and general corporate purposes. The company will need to raise substantial additional capital to continue to fund its operations and execute its current business strategy.

Industry Context

This announcement is typical for a biopharmaceutical company that is in the development stage and requires additional funding to continue its operations and clinical trials. The company is focused on women's health, which is a growing area of interest in the pharmaceutical industry.

Comparison to Industry Standards

• Many small-cap biopharmaceutical companies utilize at-the-market (ATM) offerings or similar financing arrangements to raise capital.
• The potential dilution from the sale of shares is a common risk for companies in this sector.
• The focus on women's health is a niche area, and the company's success will depend on the clinical and commercial success of its product candidates.
• The company's reliance on third-party collaborations for commercialization is also a common practice in the industry.
• The company's need to raise additional capital is typical for companies in the development stage.

Stakeholder Impact

• Shareholders may experience dilution and a potential decrease in share price.
• The company's ability to fund its operations and continue its development programs is dependent on this financing.
• The company's employees may be impacted by the company's financial performance and ability to continue operations.

Next Steps

• The company will need to satisfy the conditions set forth in the purchase agreement for the commencement of share sales to Lincoln Park.
• The company will need to monitor its market value of listed securities to maintain compliance with Nasdaq listing requirements.
• The company will need to continue to advance its product pipeline and seek additional funding as needed.

Key Dates

Keywords

Dar Bioscience, Lincoln Park Capital Fund, common stock, resale, registration statement, biopharmaceutical, women's health, Nasdaq, dilution, financing